Salivary Gland Cancers: Management Updates for the Community Otolaryngologist

Sunday, September 29, 2024

1:30 PM – 2:20 PM EDT

Location: MBCC, Lincoln Road EF

CME/MOC Credit: 1

Disclosure(s):

Ameya A. Asarkar, MD, FACS:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Mirabelle B. Sajisevi, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Wojciech K. Mydlarz, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

PROGRAM DESCRIPTION: Salivary gland malignancy is commonly encountered in routine otolaryngology practice. Although surgery forms the mainstay of the management, knowledge of different histologies and their prognosis is paramount to optimize the management of these patients. This includes the extent of surgery, management of the neck nodal basins, referral for adjuvant therapy and also the use of targeted therapy in certain cases. Recently, the WHO classification of salivary gland tumors were updated based on the prognosis of these cancers. It is important to understand these changes as they influence the management strategies and ultimately the oncologic and functional outcomes in these patients.

This panel will focus on the management algorithm of salivary gland malignancy for the community otolaryngologist. This will include recent changes being rolled out for FNA reporting of salivary gland tumors (Milan system) and management of low and intermediate grade salivary gland malignancy. Each panelist will present a 10-12 minutes talk and 20 minutes will be dedicated for case based discussion of commonly encountered scenarios in the work up and management of salivary gland tumors.

Learning Objectives:

Understand the changes made to the most recent WHO classification and reporting of salivary gland malignancy as well as the NCCN guidelines of management.
Understand the algorithm of management of low and intermediate grade salivary gland malignancy.
Recognize the indications of referral for adjuvant therapy in salivary gland malignancy.

Panelist(s)

Mirabelle B. Sajisevi, MD

Associate Professor, Residency Program Director
University of Vermont Medical Center
Burlington, VT, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.
Wojciech K. Mydlarz, MD

Assistant Professor Director, Head and Neck Surgery - National Capitol Region
Johns Hopkins University School of Medicine
Bethesda, MD, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.
JZ

Joseph Zenga, MD

Medical College of Wisconsin, USA

Disclosure information not submitted.